Anixa Biosciences, Inc. ANIX
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.38M | -10.03M | -10.31M | -10.93M | -11.12M |
| Total Depreciation and Amortization | 39.00K | 38.00K | 37.00K | 36.00K | 36.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.96M | 3.15M | 3.62M | 3.57M | 3.71M |
| Change in Net Operating Assets | 6.00K | -267.00K | -223.00K | 152.00K | 528.00K |
| Cash from Operations | -7.38M | -7.12M | -6.88M | -7.17M | -6.85M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.06M | 1.47M | 3.39M | 4.87M | 5.08M |
| Cash from Investing | 2.06M | 1.47M | 3.39M | 4.87M | 5.08M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.41M | 5.32M | 2.45M | 2.39M | 2.06M |
| Repurchase of Common Stock | -- | -- | -3.00K | -3.00K | -36.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -189.00K | -105.00K | 1.54M | -105.00K | 16.00K |
| Cash from Financing | 5.22M | 5.21M | 3.98M | 2.28M | 2.04M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -97.00K | -433.00K | 494.00K | -27.00K | 270.00K |